A new study suggests that an epilepsy drug that can be taken once a day may control seizures as well as a drug that must be taken twice a day, according to a preliminary study presented at the American Academy of Neurology’s 68th Annual Meeting (15–21 April, Vancouver, Canada).
The study compared the once-a-day drug eslicarbazepine acetate to the twice-daily drug carbamazepine for people newly diagnosed with partial seizures, which start in one area of the brain.
“Seizure control is crucial,” said study author Elinor Ben-Menachem, of Gothenburg University in Gothenburg, Sweden. “A once-a-day drug may help people stick to their medication schedule.”
For the study, 815 people newly diagnosed with partial seizures received either eslicarbazepine or carbamazepine for about six months. Participants started the study at the lowest of three dosing levels. Those who had a seizure at the lowest level were then moved up to the second dosing level. If they had another seizure, they received the highest dosing level.
A total of 71% of those taking eslicarbazepine and 76% of those taking carbamazepine were seizure-free after six months. After one year, 65% of those taking the once-daily drug were seizure-free compared to 70% of those taking the twice-daily drug.
The study was what is called a non-inferiority study, which is designed to show that a new treatment is not clinically worse than an existing treatment. According to the study design, eslicarbazepine would be considered “non-inferior” if the difference in seizure-free rate between the two drugs was 12% or lower. At six months, the difference was 4%. At one year, the difference was 5%.
“Memory issues, fatigue, or a complicated medication schedule can all interfere with a person taking their seizure-control medications on a regular basis so having a once-daily option for patients, especially when they are newly diagnosed and still learning to manage the disease, may be beneficial,” said Ben-Menachem. “The hope is that these results may also give doctors more options to better tailor treatments for people with epilepsy.”